|CD288||TLR8 (Toll-like receptor 8)|
|Molecule Type||Antigen Expression||Molecular Weight|
Min / Max
|Non-lineage Restricted Molecule|
Type 1 glycoprotein
|83 / 83|
|CD288 is expressed in endosomal or lysosomial compartments of macrophages, subsets in dendritic cells including plasmacytoid dendritic cells and leukocytes. Expression is in the lung, brain, heart, placenta, monocytes and in lower levels in CD11c+ immature dendritic cells.|
|MOLECULAR FAMILY NAME: Belongs to the Toll-like receptor family.|
CD288 is a single-pass type-1 1015 aa transmembrane glycoprotein. It contains a 26 aa signal sequence, an 801 extracellular domain which contains 24 leucine-rich repeats(LRR) capped at each end by N- and C-terminal motifs and 21 potential N-linked glycosylation sites, a 21 aa transmembrane domain and an 193 aa intracellular cytoplasmic domain which contains a Toll/IL-1R domain that interacts with the adaptor molecule myeloid differentiation primary gene MyD88. The LRRs form a "horseshoe" shaped structure which is the ligand binding domain.
POST-TRANSCRIPTIONAL MODIFICATION: No information.
CD288 has 21 potential glycosylation sites.
|LIGANDS AND MOLECULE ASSOCIATED WITH CD288 |
CD288 bind single-stranded GU-rich RNA.
|CD288 is a Toll-like receptor that forms part of the innate defence mechanism against infection by double-stranded (ds) and single-stranded (ss) RNA viruses and its recognition of single-stranded GU-rich RNA. The anti-viral response to dsRNA viruses is thought to be in part due to CD288 recognition of de novo synthesized ssRNA that accumulates during viral replication within the cell cytoplasm. CD288 plays a fundamental role in pathogen recognition and activation of innate immunity. TLRs are highly conserved from Drosophilia to humans and share structural and functional similarities. They recognize pathogen-associated molecular patterns (PAMPs) that are expressed on infectious agents, and mediate the production of cytokines necessary for the development of effective immunity. They participate in the innate immune response to microbial agents. Ligation of CD288 triggers secretion of inflammatory and regulatory cytokines. CD288 acts via MyD88 and TRAF6, leading to NF-κB activation, cytokine secretion and the inflammatory response. Recent studies have implicated CD287 in the development of an autoimmune response to self-RNA associated auto-antigens such as nucleoprotein antigens Sm and ribonucleoprotein (RNP). Sm and RNP are tightly bound to U-rich small nucleotide (sn) RNAs, which are potential ligands of CD287 (and/or CD288). SnRNA containing antigen-antibody complexes are able to activate B lymphocytes and dendritic cells via CD287 and CD288.|
BIOCHEMICAL ACTIVITY: No information.
DISEASE RELEVANCE AND FUNCTION OF CD288 IN INTACT ANIMAL: No information.
PROTEINS AND DNA ELEMENTS WHICH REGULATE TRANSCRIPTION OF CD288: No information.
SUBSTRATES: No information.
ENZYMES WHICH MODIFY CD288: No information.
Database accession numbers
Revised June 25, 2008